> Skip repeated content
Photo of Dr. Fernandez

David R. Fernandez, MD


Rheumatology
Photo of Dr. Fernandez

David R. Fernandez, MD


Hospital for Special Surgery
525 East 71st Street
Belaire Building - 7th floor
New York, NY, 10021

Tel: 212.774.7016
Fax: 646.797.8352

Hospital for Special Surgery
525 East 71st Street
Belaire Building - 7th floor
New York, NY, 10021

Tel: 212.774.7016
Fax: 646.797.8352

loading...
 

Back in the Game Patient Stories

Appointments

Assistant Attending Physician, Hospital for Special Surgery

Specialty

Specialized Centers

Special Expertise

Dermatomyositis
Polymyositis Inclusion
Body Myositis
Systemic Lupus Erythematosus

Awards

Lupus and Antiphospholipid Syndrome Center of Excellence Research Fund Award, 2016
F31 Predoctoral Fellowship, NIAMS, 2008-201

Languages

English

Insurance Information

Aetna
Blue Cross Blue Shield PPO HMO POS
Blue Cross Blue Shield Pathway
Blue Cross Blue Shield Pathway Enhanced
Cigna
Connecticare
Emblem Selectcare
HIP
Medicare
Oxford
Oxford Medicare
United Healthcare
United Healthcare Compass

Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may still have coverage subject to the availability of 'out-of-network' benefits.

Book an Appointment with Dr. Fernandez

Dr. Fernandez accepts the following insurance plans. Please check to see if your insurance is on this list before proceeding.

Aetna
Blue Cross Blue Shield PPO HMO POS
Blue Cross Blue Shield Pathway
Blue Cross Blue Shield Pathway Enhanced
Cigna
Connecticare
Emblem Selectcare
HIP
Medicare
Oxford
Oxford Medicare
United Healthcare
United Healthcare Compass

Please note, if your insurance is not on this list, you may still have coverage subject to the availability of out-of-network benefits.

If you do not wish to go out-of-network, our Physician Referral Service will help you find an appropriate doctor.

Please call our office to book an appointment.


Patient ratings for Dr. Fernandez

Education

SUNY Upstate Medical University, Syracuse

Internship

NewYork-Presbyterian - Weill Cornell Medical Center, New York

Residency

NewYork-Presbyterian - Weill Cornell Medical Center, New York

Fellowship

Hospital for Special Surgery, New York

Certification

American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Rheumatology

State Licensure

New York

Selected Publications

Fernandez D, Kirou KA. What Causes Lupus Flares? (2016) Current Rheumatology Reports. 18(3):14. doi: 1007/s11926-016-0562-3.

Fernandez DR, Markenson JA. Gout and Hyperuricemia – Serious Risk Factors for Morbidity and Mortality or Just Indicator "The Good Life" – The Evidence to Date. (2015) Current Treatment Options in Rheumatology. 1(2):167-181.

Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, Lai ZW, Miklossy G, Singh RR, Chudakov DM, Malomi W,Banki K, Perl A. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment of SLE. (2014) Annals of the Rheumatic Diseases. 73(10):1888-97. (PMCID: PMC4047212)

Fernandez D, Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? (2010) Discovery Medicine. 9(46):173-8. (PMCID: PMC4047522)

Hanczko R, Fernandez DR, Doherty E, Qian Y Vas G, Niland B, Telarico T, Garba A, Banerjee S, Middleton FA, Barrett D,Barcza M, Banki K, Landas SK, Perl A. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. (2009) Journal of Clinical Investigation. 119(6):1546-57. (PMCID: PMC2689120)

Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, Perl A. Activation of mammalian target of rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. (2009) Journal of Immunology. 182(4):2063-73. (PMCID: PMC2676112)

Perl A, Fernandez DR, Telarico T, Doherty E, Francis L, Phillips PE. T-cell and B-cell signaling biomarkers and treatment targets in lupus. (2009) Current Opinions in Rheumatology. 21(5):454-464.

Fernandez D, Bonilla E, Phillips P, Perl A. Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets. (2006) Endocrine, Metabolic & Immune Disorders – Drug Targets. 6(4):305-311.

Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. (2006) Arthritis & Rheumatism. 54(9):2983-8. (PMCID:PMC4034146)

For more publications, please see the PubMed listing.

Professional Education by Dr. Fernandez on HSS.edu

Research Interests

Currently studying the role of cell-free mitochondrial DNA in triggering interferon production and disease flares in patients with systemic lupus erythematosus, as well as the effect of medications used to treat lupus patients on mitochondrial DNA release.

Additionally, working to identify clinical features in a large cohort of lupus patients that may allow us to better define subgroups of patients.

Patient Registries